Beyond Air, Inc. (XAIR)

NCM – Real vaqt narxi. Valyuta: USD

0.54

+0.02 (3.35%)

Yopilishda: May 12, 2026, 4:00 PM EDT

0.54

+0.01 (1.01%)

Bozor oldidan: May 13, 2026, 9:17 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Beyond Air, Inc. (XAIR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Beyond Air, Inc. (XAIR)

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

Videolar

No Data

Press-relizlar

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

Search stocks

Beyond Air, Inc. (XAIR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Beyond Air, Inc. (XAIR)

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

Videolar

No Data

Press-relizlar

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections